Impact of the Landiolol on the level on serum biomarkers, catecholamines and cardiac enzymes in patients with coronary artery disease performed percutaneouse coronary intervention.

Impact of the Landiolol on the level on serum biomarkers, catecholamines and cardiac enzymes in patients with coronary artery disease performed percutaneouse coronary intervention. - Impact of the Landiolol on the level on serum biomarkers, catecholamines and cardiac enzymes in patients with coronary artery disease performed percutaneouse coronary intervention.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015802

Enrollment

Registered

2014-12-01

Start date

2015-01-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

angina pectoris

Interventions

Landiolol group Landiolol is started 15 minutes before percutaneous coronary intervention, which dose is 3 mcg/kg/min. Its injection will continue until the next day morning. Non Landiolo group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with angina pectoris who will be scheduled percutaneous coronary intervention.

Exclusion criteria

Exclusion criteria: 1. HR less than 50bpm 2. 2or3 AV block 3. Shock 4. Left main disease 5. Asthma 6. Right ventricular infarction 7. History of side effects by using beta blockers 8. Symptom of heart failure 9. Patients with malignancy, uncontrolled infection 10. Patients who need hemodialysis 11. PCI for chronic total occlusion 12. Reduced ejection fraction (<40%) 13. Pregnant 14. Patients who used Landiolol within 1 month before PCI 15. Not eligible determined by the responding physician

Design outcomes

Primary

Measure	Time frame
Difference between Landiolol group and non-Landiolol group on serum adiponectine and high molecular weight adiponectine 72 hours after percutaneous coronary intervention	—

Secondary

Measure	Time frame
Serum catecholamines level.Serum troponine level Hypotension, A-block, bradycardia and worsening heart failure while using Landiolol.	—

Countries

Japan

Contacts

Public ContactMasayoshi Kiyokuni

Yokohama City University Graduate School of Medicine Department of Medical Science and Cardiorenal Medicine

masakiyo@yokohama-cu.ac.jp045-787-2800

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026